Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer
J Clin Oncol AUG 31; 2023 Vergote Ignace et al. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results
New Indication: Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma
J Clin Oncol AUG 17; 2023 Cathomas Richard et al. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phas
New Protocol: Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
J Clin Oncol AUG 15; 2023 Slovin F. Susan et al. Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-
New Protocol: Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
J Clin Oncol AUG 30; 2023 Qin Shukui et al. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer http://doi.org/10.1200/JCO.22.02630 Re
New Protocol: First-line regorafenib with nivolumab and chemotherapy in advanced esophageal, gastric, or gastro-esophageal junction cancer
Lancet Oncol SEP 01; 2023 Cytryn L. Samuel et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in
New Drug: Pralsetinib for non-small cell lung cancer with RET gene fusions
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023
New Drug: Talquetamab-tgvs for relapsed or refractory multiple myeloma
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023
New Protocol: Niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer
J Clin Oncol 2023 41:18, 3339-3351 Chi N. Kim et al. Niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer http://doi.o
